Wolters T - Search Results

1

A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.

Wagensveld IM, Osses DF, Groenendijk PM, Zijta FM, Busstra MB, Rociu E, Barentsz JO, Michiel Sedelaar JP, Arbeel B, Roeleveld T, Geenen R, Koeter I, van der Meer SA, Cappendijk V, Somford R, Klaver S, Van der Lely H, Wolters T, Hellings W, Leter MR, Van der Poel HG, Heijmink SWTPJ, Debruyne F, Immerzeel J, Leijte J, van Roermund J, Miclea R, Planken E, Vis AN, Jan de Jong I, Tijsterman J, Wolterbeek D, Claessen A, Vrijhof E, Nederend J, Van Leenders GJLH, Bangma CH, Krestin GP, Remmers S, Schoots IG; MR-PROPER Study Group. Wagensveld IM, et al. Among authors: wolters t. Eur Urol. 2022 Sep;82(3):318-326. doi: 10.1016/j.eururo.2022.03.003. Epub 2022 Mar 24. Eur Urol. 2022. PMID: 35341658 Free article.

2

Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.

Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ. Schröder FH, et al. Among authors: wolters t. Eur Urol. 2008 Mar;53(3):468-77. doi: 10.1016/j.eururo.2007.10.047. Epub 2007 Nov 5. Eur Urol. 2008. PMID: 17997011 Review.

3

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

Wolters T, Roobol MJ, Bangma CH, Schröder FH. Wolters T, et al. Eur Urol. 2009 Feb;55(2):385-92. doi: 10.1016/j.eururo.2008.02.046. Epub 2008 Mar 11. Eur Urol. 2009. PMID: 18353529 Clinical Trial.

4

Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.

van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH. van den Bergh RC, et al. Among authors: wolters t. Eur Urol. 2008 Sep;54(3):505-16. doi: 10.1016/j.eururo.2008.06.040. Epub 2008 Jun 20. Eur Urol. 2008. PMID: 18585845 Review.

5

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, Schröder FH. Roobol MJ, et al. Among authors: wolters t. Eur Urol. 2010 Jan;57(1):79-85. doi: 10.1016/j.eururo.2009.08.025. Epub 2009 Sep 1. Eur Urol. 2010. PMID: 19733959

6

Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.

Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ. Schröder FH, et al. Among authors: wolters t. Eur Urol. 2010 Feb;57(2):256-66. doi: 10.1016/j.eururo.2009.10.031. Epub 2009 Nov 6. Eur Urol. 2010. PMID: 19913350

7

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D. Roobol MJ, et al. Among authors: wolters t. Eur Urol. 2010 Oct;58(4):475-81. doi: 10.1016/j.eururo.2010.06.039. Epub 2010 Jul 9. Eur Urol. 2010. PMID: 20637539 Clinical Trial.

8

Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100.

Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, Wolters T, Barentsz JO, Roobol MJ. Schröder FH, et al. Among authors: wolters t. Urology. 2014 Mar;83(3):613-6. doi: 10.1016/j.urology.2013.12.005. Urology. 2014. PMID: 24581524

9

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group. Roobol MJ, et al. Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25. Eur Urol. 2013. PMID: 23759326 Clinical Trial.

10

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.

Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schröder FH. Roemeling S, et al. Among authors: wolters t. Eur Urol. 2007 May;51(5):1244-50; discussion 1251. doi: 10.1016/j.eururo.2006.11.053. Epub 2006 Dec 5. Eur Urol. 2007. PMID: 17161520 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters